Eledon Pharmaceuticals Inc Sustainability Reports
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for transplantation and autoimmune diseases. Its lead compound, tegoprubart, is an anti-CD40L antibody designed to protect transplanted organs and cells from immune rejection.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300S17CAM13O43606
FIGI: BBG00241S579
3 reports from 2021 to 2023
